View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
May 4, 2018

Celyad doses first patients in SHRINK and LINK trials

Celyad has dosed the first patients in its SHRINK and LINK trials, injecting subjects with CYAD-01, an NKG2D receptor.

Celyad has dosed the first patients in its SHRINK and LINK trials, injecting subjects with CYAD-01, an NKG2D receptor.

SHRINK is an open-label Phase I trial designed to investigate the safety and clinical activity of multiple doses of CYAD-01 as a treatment for patients with resectable liver metastases from colorectal cancer.

As part of the trial, CYAD-01 will be administered concurrently with the neoadjuvant FOLFOX treatment to the enrolled patients.

The trial’s dose escalation phase includes three dose levels of CYAD-01. At each dose, the patients will be given three successive administrations two weeks apart at the specified dose.

So far, the trial has not reported any adverse events.

"We are particularly satisfied with the lack of on-target/off-tumour toxicity observed to date in the context of the combination of CYAD-01 with chemotherapy."

LINK is an open-label Phase I trial that seeks to analyse the safety and clinical activity of multiple doses of CYAD-01.

The trial will follow a loco-regional approach while treating patients with CYAD-01 administration by providing a number of hepatic transarterial injections to colorectal cancer patients diagnosed with unresectable liver metastases.

Its dose escalation phase will feature three dose levels of CYAD-01 and will be similar to that of the SHRINK trial.

Celyad CEO Dr Christian Homsy said: “CYAD-01, concurrently administered with standard chemotherapy FOLFOX in SHRINK, or administered through hepatic transarterial injections in LINK appears to have been well–tolerated to date.

“We are particularly satisfied with the lack of on-target/off-tumour toxicity observed to date in the context of the combination of CYAD-01 with chemotherapy.”

Celyad expects to begin the EPITHINK trial of CYAD-01 for the treatment of Acute Myeloid Leukemia (AML) soon.

The company also plans to initiate DEPLETHINK AML and DEPLETHINK CRC trials of CYAD-01 for AML over the next few weeks.

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU